EventHealthSeptember 2, 2026

Boehringer signs deal for Owkin AI in drug discovery

Read original source →bloomberg.com

Boehringer Ingelheim agreed to use Owkin's AI model to help discover new oncology and immunology medicines, joining AstraZeneca and Sanofi in similar partnerships.

2 sources

More stories today

Open the live feed